Zio ECG Utilization Software (ZEUS) System vs EchoGo Amyloidosis
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 65/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
Tool A, the Zio ECG Utilization Software, is designed for continuous ECG monitoring to detect and manage cardiac arrhythmias using data from wearable sensors. In contrast, Tool B, EchoGo Amyloidosis, analyzes echocardiogram video clips to screen for cardiac amyloidosis. While both are AI-powered cardiology tools, they address distinct diagnostic needs within cardiology, utilizing different data modalities and targeting different cardiac conditions.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
The Zio ECG Utilization Software (ZEUS) System is designed to aid physicians in the diagnosis and management of cardiac arrhythmias by analyzing continuous ECG data from wearable Zio monitors. In contrast, Ultromics' EchoGo Amyloidosis is an AI-powered screening tool that analyzes echocardiogram video clips to aid in the early detection of cardiac amyloidosis.
ZEUS analyzes continuous ECG data collected from wearable Zio monitors, which can be worn for up to 14 days. EchoGo Amyloidosis analyzes echocardiogram video clips, specifically a single apical four-chamber view, to identify markers suggestive of cardiac amyloidosis.
ZEUS integrates with HL7-based EHR systems and offers the ZioSuite web portal and mobile application for healthcare professionals to manage workflows and access reports. EchoGo Amyloidosis is designed for seamless integration with existing clinical workflows and IT infrastructure, including PACS, DICOM, and HL7, requiring no additional hardware or software installations.
The Zio ECG Utilization Software (ZEUS) System is intended for use by cardiologists, family medicine practitioners, and internal medicine specialists. EchoGo Amyloidosis is specifically designed to support cardiologists in the detection of cardiac amyloidosis.
ZEUS generates comprehensive end-of-wear reports for physician review, aiding in the detection and classification of various cardiac arrhythmias. EchoGo Amyloidosis provides a diagnostic output indicating whether an echocardiogram is 'suggestive' or 'not suggestive' of cardiac amyloidosis, based on its AI-powered analysis of echocardiographic markers.
More Comparisons
Backers
Who funded each tool's parent company.